INGEVITY CORP (NGVT)

Sector: Materials

    Home/Companies/NGVT/Annual Meeting

2026 Annual Meeting Analysis

INGEVITY CORP · Meeting: April 29, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

9

Directors AGAINST

0

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Directors

9 FOR
✓ FOR
Luis Fernandez-Moreno

Director since 2016 with deep specialty chemicals industry experience; the TSR trigger does not apply because Ingevity's 3-year return (-8.4%) outperformed the compensation peer group median (-14.0%) by +5.6 percentage points, which is well below the 20-point underperformance threshold needed to trigger a vote against; no overboarding, attendance, or independence concerns identified.

✓ FOR
Diane H. Gulyas

Director since 2019 with extensive chemicals and global manufacturing leadership; the TSR trigger does not apply because Ingevity outperformed its peer group median over 3 years, and she holds only 1 outside public board seat so overboarding is not a concern; all other governance checks pass.

✓ FOR
Bruce D. Hoechner

Director since 2023 and current independent Board Chair with strong materials-industry CEO background; joined within approximately 2.5 years of this meeting so any residual TSR concern is substantially mitigated by limited tenure overlap; holds 1 outside public board seat; no other flags.

✓ FOR
David H. Li

President and CEO who joined the board in April 2025, less than 24 months ago, so he is fully exempt from the TSR underperformance trigger under the new-director exemption; his appointment brings direct industry expertise and he holds 1 outside public board seat, which is within the policy limit for a sitting CEO.

✓ FOR
Frederick J. Lynch

Director since 2016 with broad manufacturing and CEO experience and designated as an audit committee financial expert; the TSR trigger does not apply because Ingevity's 3-year performance outperformed the peer group median by +5.6 percentage points; no overboarding or attendance issues identified.

✓ FOR
Karen G. Narwold

Director since 2019 with extensive legal, compliance, and sustainability expertise; TSR trigger does not apply given peer group outperformance; holds 2 outside public board seats, well within the 4-seat limit; no other governance concerns.

✓ FOR
F. David Segal

Joined the board in April 2025, less than 24 months ago, making him fully exempt from the TSR underperformance trigger; brings capital allocation and investment experience relevant to Ingevity's strategic repositioning; holds no other public company board seats.

✓ FOR
J. Kevin Willis

Director since 2024 with fewer than 24 months of tenure at the time of this meeting, exempting him from the TSR trigger; serves as Audit Committee Chair and is a designated audit committee financial expert; holds no other public company board seats.

✓ FOR
Benjamin G. (Shon) Wright

Director since 2022 with strong operational and global manufacturing experience; the TSR trigger does not apply because Ingevity outperformed its compensation peer group median over 3 years; no overboarding or attendance issues; all governance checks pass.

All nine nominees receive a FOR vote. Using the company-disclosed compensation peer group as the primary benchmark, Ingevity's 3-year price return of -8.4% outperformed the peer median of -14.0% by +5.6 percentage points, which is below the 20-point underperformance threshold required to trigger a vote against any director under the negative-absolute-TSR tier. Directors who joined within the past 24 months (Li, Segal, Willis) are additionally exempt from the TSR trigger. No overboarding, attendance below 75%, independence, or familial-relationship concerns were identified for any nominee.

Say on Pay

✓ FOR

CEO

David H. Li

Total Comp

$12,839,719

Prior Support

91%%

The prior Say-on-Pay vote received 91% support, well above the 70% threshold that would require remediation; the CEO compensation program is heavily weighted toward variable, performance-linked pay — the target pay mix shows the large majority of Mr. Li's total compensation is at-risk equity and annual incentives, meeting the 50-60% variable pay standard. Ingevity's 3-year total return (-8.4%) slightly outperformed the compensation peer group median (-14.0%), meaning above-target variable pay is not misaligned with shareholder experience; performance stock awards use meaningful metrics including relative total shareholder return versus the Russell 2000 Basic Materials Index and cumulative earnings growth measured over three years, and the 2023 performance stock awards paid out at only 24% of target, demonstrating that the plan does reduce pay when performance falls short. The company also maintains a clawback policy and a no-hedging policy, and the compensation consultant is independent.

Auditor Ratification

✓ FOR

Auditor

PricewaterhouseCoopers LLP

Tenure

N/A

Audit Fees

$2,815,000

Non-Audit Fees

$10,000

Non-audit fees of $10,000 represent only 0.4% of audit fees of $2,815,000, far below the 50% threshold that would raise independence concerns; PwC is a Big 4 firm fully appropriate for a $2.4 billion market-cap company; auditor tenure is not disclosed in the filing so the tenure trigger cannot be confirmed and does not fire; no material financial restatements are noted.

Overall Assessment

The 2026 Ingevity annual ballot presents four proposals: a director slate where all nine nominees receive FOR votes because the company's 3-year return outperformed its compensation peer group median and no individual governance flags were triggered; auditor ratification that passes cleanly with de minimis non-audit fees; a Say-on-Pay vote that merits support given a strong prior approval rate, performance-linked pay design, and demonstrated willingness to reduce payouts when targets are missed. The equity plan amendment (Proposal 4) falls outside the scope of the current voting policy and is noted but not scored.

Filing date: March 17, 2026·Policy v1.2·high confidence

Compensation Peer Group

37 companies disclosed in 2026 proxy filing

ASIXAdvanSix Inc.
ATECAlphatec Holdings, Inc.
ANGOAngioDynamics, Inc.
ANIKAnika Therapeutics, Inc.
AORTArtivion, Inc.
ASHAshland Inc.
ATRCAtriCure, Inc.
AVNSAvanos Medical, Inc.
AVNTAvient Corp.
BCPCBalchem Corp.
BVSBioventus Inc.
CBTCabot Corp.
CNMDCONMED Corporation
CUTRCutera, Inc.
ECVTEcovyst Inc.
ESIElement Solutions Inc
FULH.B. Fuller Co.
HXLHexcel Corp.
IOSPInnospec Inc.
IARTIntegra LifeSciences Holdings Corporation
KOPKoppers Holdings Inc.
LMATLeMaitre Vascular, Inc.
MATVMativ Holdings, Inc.
MDXGMiMedx Group, Inc.
MTXMinerals Technologies Inc.
NUVANuVasive, Inc.
OSUROraSure Technologies, Inc.
OECOrion S.A.
OFIXOrthofix Medical Inc.
PCRXPacira BioSciences, Inc.
KWRQuaker Chemical Corp.
SXTSensient Technologies Corp.
SCLStepan Co.
TROXTronox Holdings
VNDAVanda Pharmaceuticals Inc.
Verical Corporation
ZIMVZimVie Inc.